We Develop High-Quality Biosimilars. For Better Access to Vital Medicines.

Our focus is on treatments in ophthalmology and immunology as well as for other key chronic diseases. Our company's activities span the entire range from technical-pharmaceutical development to clinical trials, all the way through to preparation of dossiers for regulatory approval.

Half-Year Report 2023

Formycon. The Biosimilar Experts.

COVID-19 Project: FYB207

An innovative antiviral drug based on a long-acting ACE2-IgG-Fc fusion molecule

Discover Formycon

Biosimilar developer with unique expertise

Latest News News Upcoming Events Events Publications Publications

Convincing overall performance – Formycon reports preliminary results for the financial year 2023 and exceeds forecast

April 12, 2024

Formycon AG publishes preliminary figures for the 2023 financial year and guidance for the 2024 financial year

April 12, 2024

Formycon announces commercial launch of FYB201 (Ranibizumab) in Canada (Ranopto^TM) and Switzerland (Ranivisio®)

April 11, 2024

Meet your New Colleagues

Formycon’s employees are the foundation of our success. We strongly believe that an appreciative corporate culture contributes significantly to our progress. Therefore, we cultivate a culture of diversity and mutual appreciation.

We offer you the opportunity for rapid career advancement in a dynamic, high-growth environment where professionalism and team spirit form the foundation of our daily cooperation.

Explore your career opportunities

Facts & Insights

Key Figures

Biosimilar Pipeline

Product	Originator	Preclinical Phase	Clinical Phase I	Clinical Phase III
FYB201	Lucentis®
FYB202	Stelara®
FYB203	Eylea®
FYB206	Keytruda®
FYB208	undisclosed
FYB209	undisclosed